Anti-SARS-CoV-2 Nucleocapsid (N) (Clone NP1-F3)
| Code | Size | Price |
|---|
| LEI-LT7050-100ug | 100 ug | £408.00 |
Quantity:
| LEI-LT7050-500ug | 500 ug | £729.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: Human IgG1
Antibody Clonality: Monoclonal
Antibody Clone: NP1-F3
Regulatory Status: RUO
Target Species:
- SARS-CoV-2
- Virus
Application: Enzyme-Linked Immunosorbent Assay (ELISA)
Shipping:
Blue Ice
Storage:
This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Further Information
Antigen Distribution:
The nucleocapsid protein is expressed in the internal nucleocapsid of SARS-CoV-2.
Concentration:
? 5.0 mg/ml
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Formulation:
This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Immunogen:
SARS-CoV-2 Nucleocapsid (N) Protein
Long Description:
Coronavirus disease 2019 (COVID-19) is caused by the Coronaviridae family virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)1. SARS-CoV-2 has four structural proteins encoded by its single-stranded, positive-sense RNA genome: the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins2. The N protein is a highly conserved 46 kDa protein that shares 90% homology with SARS-CoV3. The N protein has an N-terminal (NTD) and C-terminal domain (CTD), which bind to RNA and self-oligomerize, respectively4,5, forming a helical nucleocapsid structure within the viral envelope6. Other functions of the N protein included viral transcription, replication, and modulating cell signaling pathways7,8. The N protein is abundantly expressed during infection, and antibodies3,9 and memory T cells10,11 targeting the N protein have been identified in convalescent sera. Therefore, the N protein is a target in some vaccines and diagnostic assays12. The N protein also has therapeutic potential, as it evades RNAi-mediated antiviral responses13.
NCBI Gene:
43740575
Purity:
?95% monomer by analytical SEC
Target:
SARS-CoV-2 Nucleocapsid (N)
References
1. Zhou, P., Yang, X., Wang, X. et al. Nature 579, 270?273. 2020.
2. Wu, F., Zhao, S., Yu, B. et al. Nature 579, 265?269. 2020.
3. Guo L., Ren L., Yang S., et al. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America. 2020.
4. Kang S, Yang M, Hong Z, et al. Acta Pharm Sin B. 10.1016/j.apsb.2020.04.009. 2020.
5. Chang CK, Sue SC, Yu TH, et al. J Biomed Sci. 13(1):59-72. 2006.
6. Hsieh PK, Chang SC, Huang CC, et al. J Virol. 79(22):13848-13855. 2005.
7. Surjit M, Lal SK. Infect Genet Evol. 8(4):397-405. 2008.
8. Hurst KR, Ye R, Goebel SJ, Jayaraman P, Masters PS. J Virol. 84(19):10276-10288. 2010.
9. To K.K., Tsang O.T., Leung W.S., et al. Lancet Infect. Dis. 2020.
10. Grifoni A., Weiskopf D., Ramirez S.I., et al. Cell. 2020.
11. Ni L, Ye F, Cheng ML, et al. Immunity. 52(6):971-977.e3. 2020.
12. Liu L, Liu W, Zheng Y, et al. Microbes Infect. 22(4-5):206-211. 2020.
13. Mu J, Xu J, Zhang L, et al. Sci China Life Sci. 1-4. 2020.
Related Products
| Product Name | Product Code | Supplier | Anti-SARS-CoV-2 Spike RBD (Clone: 2165) | LEI-LT1900 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-SARS-CoV-2 Spike NTD (Clone 2146) | LEI-LT2000 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-SARS-CoV-2 Spike RBD (Clone: 2838) | LEI-LT3000 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-SARS-CoV-2 Spike RBD (Clone: 2381) | LEI-LT4000 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-SARS-CoV-2 Spike RBD (Clone: 2355) | LEI-LT5000 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-SARS-CoV-2 Spike NTD (Clone 2215) | LEI-LT6000 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant SARS-CoV-2, Nucleocapsid (N) Protein | LEI-S854 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||